NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
Molecular insights into cell signaling pathways in kidney stone formation
It definitely helps control your appetite, and you feel sick if you eat too much
What is the mechanism with specific numbers
This approach helps reduce digestive side effects while improving appetite control and metabolic balance
In in-vitro and experimental research models, BPC-157 is primarily used to analyze peptide signaling pathways, cellular response mechanisms, and molecular interactions within controlled biological systems
